Amaris Clinical

Amaris Clinical is a division of Caplin Point Laboratories, a rapidly growing mid-cap pharmaceutical company in India. Established in 2018, the company prides itself on its futuristic ideas, eminent data, and a dedicated team focused on exceeding client expectations. With a strong emphasis on building relationships and providing comprehensive clinical and drug development services, Amaris Clinical ensures the successful transformation of molecules into medicinal products. All employees undergo rigorous training and approval processes to maintain the highest standards of conduct and service quality. The company's expertise, therapeutic alignment, and commitment to excellence are evident in every study.

Caplin Point Laboratories, the parent company, boasts over 2000 product licenses globally and operates a cutting-edge manufacturing facility for injectables, which holds approvals from EU-GMP, ANVISA, and US-FDA. This strategic alignment provides Amaris Clinical with a strong foundation and resources to drive continued growth and success.

While details about its headquarters, last investment, and investors are not available, Amaris Clinical is well-positioned to capitalize on the thriving biotechnology, healthcare, and health and wellness industries. Its affiliation with Caplin Point Laboratories lends it substantial credibility and resources.